In the pharmaceutical industry, Glibenclamide (also known as Glyburide) is a potent second-generation sulfonylurea used to manage Type 2 Diabetes. As a pharmacist and manufacturer, I can confirm that Glibenclamide can be taken twice a day, but this depends entirely on your total daily dose and your physician’s specific instructions.
At your WHO-GMP facility in Mumbai, you likely manufacture this in 2.5 mg and 5 mg strengths.
Dosing Protocols
The frequency of administration is usually determined by the total dosage required to maintain glycemic control:
-
Once-Daily Dosing: Typically, if the total dose is 5 mg or less, it is taken as a single dose with breakfast or the first main meal of the day.
-
Twice-Daily Dosing: If the required dose exceeds 5 mg or 10 mg, your doctor may split it into two doses—one in the morning and one in the evening—to provide more stable blood sugar control throughout the day.
-
Maximum Dose: The total daily dose should generally not exceed 20 mg.
Mechanism: Stimulating Insulin Secretion
Glibenclamide works by forcing the pancreas to release more of its own insulin.
Receptor Binding: It binds to the Sulfonylurea Receptor (SUR1) on the surface of pancreatic beta cells.
Channel Closure: This binding closes the ATP-sensitive potassium ($K_{ATP}$) channels.
Depolarization: The closure causes the cell membrane to depolarize, which opens voltage-gated calcium channels.
Insulin Release: The influx of calcium triggers the exocytosis (release) of insulin granules into the bloodstream, which then lowers blood glucose.
The Pharmacist’s “Safety Check”
As you promote your pharmaceutical firm online, providing these technical warnings is essential for professional authority:
-
Hypoglycemia Risk: Because Glibenclamide is very potent and has a long duration of action (up to 24 hours), the risk of low blood sugar (hypoglycemia) is higher than with newer drugs. This is especially true if a meal is skipped after taking the dose.
-
Weight Gain: Sulfonylureas are often associated with modest weight gain due to increased insulin levels.
-
Beers Criteria: In the elderly, Glibenclamide is often avoided because its long half-life increases the risk of prolonged, severe hypoglycemia.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
-
The “Niche Market” USP: While many Western markets have moved to newer agents, Glibenclamide remains a high-volume, cost-effective essential medicine for many developing nations. Highlight its affordability and WHO-standard quality on your marketplace.
-
Stability & Packaging: Glibenclamide is relatively stable but should be protected from light and moisture. Utilizing Alu-Alu blister packaging ensures a 36-month shelf life, vital for export to Zone IVb tropical regions.
-
FDC Innovation: Consider highlighting Glibenclamide + Metformin combinations on your e-commerce platform. These Fixed-Dose Combinations are highly preferred for improving patient compliance.
-
Dossier Support: We provide full CTD/eCTD Dossiers for Glibenclamide to support your firm’s registration in international health tenders.